about
Biomechanical considerations in slipped capital femoral epiphysis and insights into prophylactic fixationLocal delivery of recombinant human bone morphogenetic proteins and bisphosphonate via sucrose acetate isobutyrate can prevent femoral head collapse in Legg-Calve-Perthes disease: a pilot study in pigs.Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myelomaDisruption of glucocorticoid signaling in chondrocytes delays metaphyseal fracture healing but does not affect normal cartilage and bone developmentBisphosphonate-adsorbed ceramic nanoparticles increase bone formation in an injectable carrier for bone tissue engineering.Fabrication of a Biodegradable Implant with Tunable Characteristics for Bone Implant Applications.Local delivery of the cationic steroid antibiotic CSA-90 enables osseous union in a rat open fracture model of Staphylococcus aureus infection.Activated protein C (APC) can increase bone anabolism via a protease-activated receptor (PAR)1/2 dependent mechanism.Sclerostin Antibody Increases Callus Size and Strength but does not Improve Fracture Union in a Challenged Open Rat Fracture Model.A Combination of rhBMP-2 (Recombinant Human Bone Morphogenetic Protein-2) and MEK (MAP Kinase/ERK Kinase) Inhibitor PD0325901 Increases Bone Formation in a Murine Model of Neurofibromatosis Type I Pseudarthrosis.BMP-2 delivered via sucrose acetate isobutyrate (SAIB) improves bone repair in a rat open fracture model.Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfectaRAP-011 augments callus formation in closed fractures in ratsCSA-90 reduces periprosthetic joint infection in a novel rat model challenged with local and systemic Staphylococcus aureusOptimized Synthesis of Poly(deoxyribose) Isobutyrate, a Viscous Biomaterial for Bone Morphogenetic Protein-2 DeliveryA Bioactive Coating Enhances Bone Allografts in Rat Models of Bone Formation and Critical Defect Repair
P50
Q33647107-A52B87BE-7F4C-4E46-9CE3-DD45E082E8A4Q33808678-2A63BEA3-3E81-4939-A9D6-BB4D86CE79A5Q33856318-10EC62C9-7341-455D-81C9-353FCF9A69A2Q34824502-9722410E-43CE-47FD-8C08-037F70DC2487Q36347762-FAD32AC6-ECE4-4099-8AA1-6873D5C4E835Q38769106-068CC1B1-72B9-40D9-B29F-E763870D2C27Q41475123-7AFC6B17-662F-4330-A4BF-5E10EA53A541Q45073367-E76626D4-F845-42A7-A157-FB22A8C07DADQ47222205-5C94C3B2-0D56-42C8-B4A6-7B7427723585Q51068050-B5BCCE8B-0108-416E-B313-98B64397E5DEQ51602469-3B435BCE-8926-4419-BA62-6551BD19B3CEQ60622762-C77C92C3-3E32-4115-90D0-3790E1E1AF28Q60622763-C11A4C26-DF15-4AC0-9B72-A92D1B3BEB03Q89490458-345D977D-18DA-4FFF-8D8E-DEC8A993016DQ90774108-86D7DEBE-4C67-4BB4-A6BE-3DA9EBFFBE39Q91702481-E68AF1D1-F059-4212-B5B5-70B13428AB50
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Tegan L Cheng
@es
Tegan L. Cheng
@en
Tegan L. Cheng
@nl
Tegan L. Cheng
@sl
type
label
Tegan L Cheng
@es
Tegan L. Cheng
@en
Tegan L. Cheng
@nl
Tegan L. Cheng
@sl
prefLabel
Tegan L Cheng
@es
Tegan L. Cheng
@en
Tegan L. Cheng
@nl
Tegan L. Cheng
@sl
P1053
A-3851-2014
P106
P1153
54794786100
P21
P31
P3829
P496
0000-0002-4208-7242
P569
2000-01-01T00:00:00Z